secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2022-09-14T23:59:59+00:00
Accession:  0001193125-22-244711
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix appoints Edward C. Saltzman to board of directors
-------------------------------------------------------

- Appointed effective Sept 12, 2022 as Class II director with term through 2025 annual meeting.
- Received initial option for 50,000 shares vesting over 3 years; annual option of 25,000 shares.
- Will serve on Compensation Committee and Development Advisory Committee.
- Saltzman has over 30 years biopharma strategy experience, currently Head of Biotech Strategy at Lumanity.
- Founder of Defined Health, sold to Cello Health; brings strategic development expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/0001193125-22-244711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312522244711/d408311d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-244711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer